A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

A Phase 1/2 Study of Oncobax®-AK Administered in Combination With Immunotherapy To Patients With Advanced Solid Tumors

A Study of Oncobax®-AK in Patients With Advanced Solid Tumors (NCT05865730) is a Phase 2 interventional studying Carcinoma, Renal Cell and Carcinoma, Non-Small-Cell Lung, sponsored by EverImmune. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

Akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. Analysis of the gut microbiota of NSCLC or RCC patients shows that the presence of Akkermansia is associated with the clinical efficacy of immunotherapy. In preclinical models, oral administration of the Akkermansia p2261 strain reverses resistance to PD-1 blockade. In the clinical setting, it is therefore hypothesized that the oral administration of Oncobax®-AK to cancer patients under immunotherapy, but whose gut microbiota is deficient in Akkermansia will restore / improve the efficacy of immunotherapy in patients with NSCLC or RCC.

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against Carcinoma, Renal Cell and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

Target enrollment of 122 participants puts this in the typical range for a Phase 2-style efficacy study or a moderate Phase 3 trial in a focused Carcinoma, Renal Cell subpopulation. At this scale, the study has enough statistical power to detect a clear treatment effect but is not the largest cohort in the field.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age \> 18 years 2. diagnosed by tissue sample (biopsy-confirmed) Stage IV non-squamous NSCLC or clear cell RCC 3. NSCLC-specific criterion: Best tumor response (by iRECIST) as Stable Disease 4. NSCLC-specific criterion: PD-L1 expression \> 50% 5. ECOG Performance Status = 0-1 6. Negative stool PCR test for Akkermansia 7. At least one measurable lesion per iRECIST 8. blood count (hemoglobin) at least 100 g/L 9. Albumin \> 35 g/L 10. Signed willing to sign a consent form Who Should NOT Join This Trial: 1. Symptomatic brain metastases 2. AST or ALT \> 5 x ULN 3. Calculated creatinine clearance \< 45 ml/min 4. Auto-immune diseases requiring systemic therapy 5. Immunosuppressive therapy (\> 10 mg prednisone/day equivalent) 6. Radiotherapy (\> 30 Gy) to the lung(s) within 6 months of signed willing to sign a consent form 7. Active infection 8. Co-morbidities that may increase the risk of treatment-related adverse events 9. Pregnancy 10. Inability to comply with protocol-specific assessments Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Age \> 18 years 2. Histologically confirmed Stage IV non-squamous NSCLC or clear cell RCC 3. NSCLC-specific criterion: Best tumor response (by iRECIST) as Stable Disease 4. NSCLC-specific criterion: PD-L1 expression \> 50% 5. ECOG Performance Status = 0-1 6. Negative stool PCR test for Akkermansia 7. At least one measurable lesion per iRECIST 8. Hemoglobin ≥ 100 g/L 9. Albumin \> 35 g/L 10. Signed informed consent Exclusion Criteria: 1. Symptomatic brain metastases 2. AST or ALT \> 5 x ULN 3. Calculated creatinine clearance \< 45 ml/min 4. Auto-immune diseases requiring systemic therapy 5. Immunosuppressive therapy (\> 10 mg prednisone/day equivalent) 6. Radiotherapy (\> 30 Gy) to the lung(s) within 6 months of signed informed consent 7. Active infection 8. Co-morbidities that may increase the risk of treatment-related adverse events 9. Pregnancy 10. Inability to comply with protocol-specific assessments

Treatments Being Tested

OTHER

Live Bacterial Product - Akkermansia muciniphila

Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.

Locations (4)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

CHU Ambroise Paré

Mons, Belgium

Centre Georges Francois Leclerc

Dijon, France

Institut Gustave Roussy

Paris, France

ICANS - Institut de cancérologie Strasbourg

Strasbourg, France

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT05865730), the sponsor (EverImmune), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT05865730 clinical trial studying?

Akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. Analysis of the gut microbiota of NSCLC or RCC patients shows that the presence of Akkermansia is associated with the clinical efficacy of immunotherapy. In preclinical models, oral administration of the Akkermansia p2261 strain reverses resistance to PD-1 blockade. In the clinical setting, it is therefore hypothesized that the oral administration of Oncobax®-AK to cancer patients under immunotherapy, but whose gut microbiota is deficient in Akkermansia will restore / improve the effi… The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Who can participate in NCT05865730?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT05865730?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT05865730. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT05865730. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.